𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Application of the poser criteria in primary progressive multiple sclerosis

✍ Scribed by G. V. McDonnell; S. A. Hawkins

Publisher
John Wiley and Sons
Year
1997
Tongue
English
Weight
237 KB
Volume
42
Category
Article
ISSN
0364-5134

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

The prevalence of primary sjΓΆgren's synd
The prevalence of primary sjΓΆgren's syndrome in a multiple sclerosis population
✍ Dr. J. H. Noseworthy; B. H. Bass; M. K. Vandervoort; G. C. Ebers; G. P. A. Rice; πŸ“‚ Article πŸ“… 1989 πŸ› John Wiley and Sons 🌐 English βš– 370 KB πŸ‘ 1 views

A central nervous system illness closely resembling multiple sclerosis has been described in patients with primary Sjogren's syndrome. From these reports, the estimated prevalence of this syndrome could be similar to that of multiple sclerosis in a high-frequency area. We evaluated 192 consecutive p

Glatiramer acetate in primary progressiv
Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial
✍ Jerry S. Wolinsky; Ponnada A. Narayana; Paul O'Connor; Patricia K. Coyle; Corey πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 349 KB πŸ‘ 1 views

## Abstract ## Objective To determine whether glatiramer acetate (GA) slows accumulation of disability in primary progressive multiple sclerosis. ## Methods A total of 943 patients with primary progressive multiple sclerosis were randomized to GA or placebo (PBO) in this 3‐year, double‐blind tri

Rituximab in patients with primary progr
Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial
✍ Kathleen Hawker; Paul O'Connor; Mark S. Freedman; Peter A. Calabresi; Jack Antel πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 158 KB πŸ‘ 2 views

## Abstract ## Objective Rituximab, a monoclonal antibody selectively depleting CD20+ B cells, has demonstrated efficacy in reducing disease activity in relapsing‐remitting multiple sclerosis (MS). We evaluated rituximab in adults with primary progressive MS (PPMS) through 96 weeks and safety thro